Vaccines in clinical development
Chikungunya virus VLP vaccine.
MVA-BN WEV is a multi-valent vaccine candidate developed under contracts with the US government to address the unmet medical need for a vaccine against western, eastern and Venezuelan equine encephalitis viruses, which are rare, but potentially deadly viruses transmitted to humans by mosquitos.
TAEK-VAC is a novel immuno-oncology candidate employing our MVA-BN technology. A Phase 1 open label trial of intravenous administration of the vaccine is ongoing in patients with advanced HER2 and brachyury-expressing cancers.